isoniazid has been researched along with Hepatitis B Virus Infection in 17 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study is designed to conduct, the analysis on the curative effect of Lamivudine in treating liver function lesion caused by hepatitis B combined anti-TB drugs." | 9.27 | Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs. ( Han, Y; Xia, S; Zhou, J, 2018) |
| "The present study is designed to conduct, the analysis on the curative effect of Lamivudine in treating liver function lesion caused by hepatitis B combined anti-TB drugs." | 5.27 | Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs. ( Han, Y; Xia, S; Zhou, J, 2018) |
| "Isoniazid did not cause greater hepatotoxicity in hepatitis B carriers than in noncarriers." | 5.27 | Isoniazid prophylaxis in hepatitis B carriers. ( London, WT; Lustbader, ED; McGlynn, KA; Murphy, EC; Sharrar, RG, 1986) |
| " Key recent developments to address HIV-related TB among PWIDs include the use of simplified symptom-based algorithm to provide isoniazid-preventive therapy, molecular DNA detection methods for Mycobacterium tuberculosis and the immediate provision of antiretroviral therapy within the first 2 weeks of initiation of anti-TB treatment." | 4.88 | Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. ( Getahun, H; Gunneberg, C; Raviglione, M; Sculier, D; Verster, A, 2012) |
| " Latent tuberculosis was diagnosed at baseline and the patient was treated with isoniazid for 9 months." | 3.76 | Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis. ( Ferguglia, G; Laria, G; Prestinari, F, 2010) |
| "To determine whether inactive hepatitis B surface antigen (HBsAg) carriers are at a higher risk of drug-induced hepatotoxicity than control subjects during antituberculosis treatment with standard short-course regimens of isoniazid, rifampin, ethambutol, and/or pyrazinamide." | 3.73 | Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. ( Choi, MS; Chung, MP; Kim, H; Koh, WJ; Kwon, OJ; Lee, BH; Suh, GY, 2005) |
| "Serologic markers for hepatitis viruses were studied in 40 children who developed acute hepatitis during antituberculosis therapy with rifampin and isoniazid, with the aim of assessing the contributory role of these viruses toward producing hepatic injury." | 3.68 | Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis? ( Govil, YC; Kumar, A; Mehotra, R; Misra, PK; Rana, GS, 1991) |
| " The main factors increasing the risk of hepatic toxicity was a high dosage of INH and overall malnutrition." | 1.28 | [Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus]. ( Boguikouma, JB; Gahouma, D; Gendrel, D; Mouba, JF; Moussavou, A; Nardou, M, 1989) |
| "Isoniazid did not cause greater hepatotoxicity in hepatitis B carriers than in noncarriers." | 1.27 | Isoniazid prophylaxis in hepatitis B carriers. ( London, WT; Lustbader, ED; McGlynn, KA; Murphy, EC; Sharrar, RG, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, Y | 1 |
| Xia, S | 1 |
| Zhou, J | 1 |
| Thee, S | 1 |
| Krüger, R | 1 |
| von Bernuth, H | 1 |
| Meisel, C | 1 |
| Kölsch, U | 1 |
| Kirchberger, V | 1 |
| Feiterna-Sperling, C | 1 |
| Adamu, B | 1 |
| Abdu, A | 1 |
| Abba, AA | 1 |
| Borodo, MM | 1 |
| Tleyjeh, IM | 1 |
| Cheung, I | 1 |
| Collins, RA | 1 |
| Prestinari, F | 1 |
| Ferguglia, G | 1 |
| Laria, G | 1 |
| Getahun, H | 1 |
| Gunneberg, C | 1 |
| Sculier, D | 1 |
| Verster, A | 1 |
| Raviglione, M | 1 |
| Lee, BH | 1 |
| Koh, WJ | 1 |
| Choi, MS | 1 |
| Suh, GY | 1 |
| Chung, MP | 1 |
| Kim, H | 1 |
| Kwon, OJ | 1 |
| Valencia Ortega, ME | 1 |
| Yu, WC | 1 |
| Lai, ST | 1 |
| Chiu, MC | 1 |
| Chau, TN | 1 |
| Ng, TK | 1 |
| Tam, CM | 1 |
| Walker, PF | 1 |
| Türktaş, H | 1 |
| Unsal, M | 1 |
| Tülek, N | 1 |
| Orüç, O | 1 |
| Patel, PA | 1 |
| Voigt, MD | 1 |
| Kumar, A | 1 |
| Misra, PK | 1 |
| Mehotra, R | 1 |
| Govil, YC | 1 |
| Rana, GS | 1 |
| Wu, JC | 1 |
| Lee, SD | 1 |
| Yeh, PF | 1 |
| Chan, CY | 1 |
| Wang, YJ | 1 |
| Huang, YS | 1 |
| Tsai, YT | 1 |
| Lee, PY | 1 |
| Ting, LP | 1 |
| Lo, KJ | 1 |
| Gendrel, D | 1 |
| Nardou, M | 1 |
| Mouba, JF | 1 |
| Gahouma, D | 1 |
| Moussavou, A | 1 |
| Boguikouma, JB | 1 |
| McGlynn, KA | 1 |
| Lustbader, ED | 1 |
| Sharrar, RG | 1 |
| Murphy, EC | 1 |
| London, WT | 1 |
| Seki, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744] | Phase 4 | 25 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for isoniazid and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hepatitis B; | 2014 |
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services.
Topics: Antitubercular Agents; Chemoprevention; Comorbidity; Harm Reduction; Hepatitis B; Hepatitis C; HIV I | 2012 |
1 trial available for isoniazid and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B | 2018 |
14 other studies available for isoniazid and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany.
Topics: Adolescent; Berlin; Chemoprevention; Female; Germany; Hepatitis B; Humans; Isoniazid; Latent Tubercu | 2019 |
Projects related to respiratory infectious diseases, gastrointestinal diseases, viral hepatitis, and miscellaneous infection.
Topics: Antimicrobial Cationic Peptides; Cathelicidins; Guanine; Helicobacter Infections; Hepatitis B; Human | 2015 |
Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis.
Topics: Antitubercular Agents; Etanercept; Hepatitis B; Humans; Immunoglobulin G; Immunologic Factors; Isoni | 2010 |
Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Topics: Adult; Antitubercular Agents; Carrier State; Case-Control Studies; Chemical and Drug Induced Liver I | 2005 |
[Medicine and television: a diagnosis history].
Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C | 2005 |
Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection.
Topics: Antitubercular Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B; Humans; Isoniazid; | 2006 |
Health care of Indochinese refugees.
Topics: Cambodia; Hepatitis B; Humans; Isoniazid; Laos; Parasitic Diseases; Refugees; Tuberculosis; United S | 1984 |
Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis.
Topics: Acute Disease; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; D | 1994 |
Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child | 2002 |
Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Hepatitis A; Hepatitis B; H | 1991 |
Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.
Topics: Carrier State; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female | 1990 |
[Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus].
Topics: Adolescent; Africa; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Drug Combinatio | 1989 |
Isoniazid prophylaxis in hepatitis B carriers.
Topics: Adult; Alanine Transaminase; Asia, Southeastern; Carrier State; Child; Hepatitis B; Hepatitis B Surf | 1986 |
[Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
Topics: Aspartic Acid; Blood Transfusion; Female; Hepatitis; Hepatitis B; Humans; Isoniazid; Male; Ornithine | 1966 |